Type 1 Diabetes

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee recommended not approving sotagliflozin for glucose control as an adjunct to insulin in adults with type 1 diabetes and CKD.

Five years after receiving a complete response letter from the agency, Lexicon Pharmaceuticals brought sotagliflozin back before an FDA advisory panel to seek an indication to treat patients with type 1 diabetes and chronic kidney disease.

Prescriptions for GLP-1 receptor agonists and SGLT2 inhibitors for patients with type 1 diabetes rose between 2010 and 2023 despite not being approved for that population, according to a research letter published in JAMA.

Researchers found that women who slept less than 7 hours per night at 24 to 28 weeks’ gestation were more likely to have a child with neurodevelopmental delays compared with those who slept 7 hours or more per night.

The FDA has lifted a clinical hold on two trials assessing an investigational treatment for people with type 1 and type 2 diabetes, Biomea Fusion announced.

Both children and adults are more likely to be diagnosed with type 1 diabetes if they have a father with type 1 diabetes vs. a mother with the condition, according to a speaker.

In a small study of patients with type 1 diabetes using an automated insulin delivery system, semaglutide improved glucose control vs. placebo, researchers reported at the European Association for the Study of Diabetes Annual Meeting.

Adults with type 1 diabetes using either semaglutide or tirzepatide off-label had greater decreases in body weight and HbA1c than those not treated with either medication, according to a speaker.

Higher consumption of rye, oats and fruits increased the risk for progression to type 1 diabetes among children at high genetic risk for the disease, study results showed.

The FDA has cleared a continuous glucose monitoring system with an implantable sensor that can be worn for up to 1 year for adults aged 18 years and older with type 1 or type 2 diabetes, according to a press release.